EpimAb Biotherapeutics is a biopharmaceutical company specializing in bispecific antibodies focused around immune-oncology. All bispecifics are based on a proprietary platform, FIT-Ig (Fabs in Tandem) and multiple FIT-Igs have already been successfully generated binding to small, large, soluble, or membrane-bound antigens with biochemical and biophysical properties similar to their parent monospecific antibodies. EpimAb closed a $120 million Series C financing round co-led by China Merchants Bank International (CMBI) and Mirae Asset Financial Group (Mirae).